Skip to main content

Cheshire and Wirral Partnership NHS Foundation Trust: Remdesivir

Question for Department of Health and Social Care

UIN 95007, tabled on 24 September 2020

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that Cheshire and Wirral Partnership NHS Foundation Trust has adequate stock and future supply of remdesivir to help treat covid-19 patients.

This answer is the replacement for a previous holding answer.

Answered on

22 October 2020

Remdesivir has been granted a conditional marketing authorisation for use in hospitalised patients with COVID-19, pneumonia and on supplemental oxygen. NHS England and NHS Improvement have published an interim commissioning policy, which specifies the clinical criteria for use in the National Health Service. The United Kingdom is participating in a joint procurement for remdesivir that has been arranged by the European Commission and the NHS currently has sufficient stock for use in line with the published clinical criteria.

In addition to remdesivir, the corticosteroids dexamethasone and hydrocortisone have been proven through clinical trials to be effective treatments for patients with COVID-19. The UK has secured supplies of both drugs for use in COVID-19 and they are now routinely available to NHS patients.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.